Esophageal Adenocarcinoma

P2/3, N=126, Not yet recruiting, AstraZeneca AB

P1/2, N=45, Not yet recruiting, Gilead Sciences Inc.

P=N/A, N=2500, Recruiting, Sun Yat-sen University | Completed --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026

Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.

P=N/A, N=750, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028

In conclusion, this study provides a comprehensive pan-cancer characterization of CHRNA7, offering novel insights into its potential role as a prognostic biomarker and immunotherapeutic target. These findings could facilitate the development of personalized cancer treatment strategies customized according to the expression level and functional status of CHRNA7.

P1/2, N=26, Not yet recruiting, Gilead Sciences Inc.

We delineate three critical resistance domains common to upper gastrointestinal adenocarcinomas: (1) The "Excluded" Niche, where specific cancer-associated fibroblast (CAF) subpopulations (iCAFs vs. myCAFs) and stiffened extracellular matrix create hypovascular zones that limit drug delivery; (2) the "Immune-Tolerant" Niche, characterized by the spatial exclusion of CD8+ T cells and the recruitment of suppressive myeloid populations via the MIF/CD74 and USP14 axes; and (3) the "Metabolic" Niche, where mitochondrial heterogeneity and lipid metabolic symbiosis establish nutrient-deprived niches that select for stem-like, dormant states. By mapping these conserved spatial determinants from primary GEJ tumors to peritoneal and distant metastases, we argue that overcoming resistance requires an advancement: moving beyond targeting individual mutations to dismantling the multicellular architecture that sustains malignancy.

P=N/A, N=12000, Enrolling by invitation, The First Affiliated Hospital of Henan University of Science and Technology

These findings suggest LGALS3 as a promising diagnostic and prognostic biomarker, and a potential therapeutic target to enhance immune responses in GI cancers.

Furthermore, we will briefly discuss endoscopic treatment, chemotherapy, and surgical treatment for GEJ cancer. Looking ahead, the reclassification of GEJ cancers using the Kyoto international consensus, coupled with comprehensive molecular analyses of tumors, promises to yield valuable insights.

Treatment with JTE013 decreased tumor cell proliferation and reduced S1PR2 and α-SMA expression in OE33 cells. Together, our study suggested that [18F]TZ9555 has a substantial preclinical and clinical potential for assessing S1PR2 expression in predicting EAC progression.